A clinical-stage biotech firm advancing proprietary T-cell receptor immunotherapies for solid tumor oncology with significant R&D investment and a robust cash balance.
IOVA offers high-risk, high-reward potential with its proprietary T-cell receptor platform showing promise in solid tumor treatment where other therapies have struggled. The company's substantial cash runway and lack of debt provide flexibility to advance multiple clinical programs without immediate need for dilutive financing. Successful data readouts from upcoming trials could trigger significant value appreciation as the stock price often re-rates upon positive clinical milestones.
Investors should exercise caution given the consistent net losses exceeding $390M annually and a retained earnings deficit of nearly $2.8B, signaling ongoing financial instability. The lack of approved products means all revenue is non-recurring milestone income, making cash flow highly volatile and dependent on partner negotiations. If clinical trials fail or regulatory approval is delayed, the company could face an existential liquidity crisis despite its current cash balance.
IOVANCE BIOTHERAPEUTICS, INC. (NASDAQ: IOVA) is a clinical-stage biotechnology company focused on developing novel immunotherapies for oncology, leveraging its proprietary T-cell receptor technologies to target solid tumors. The company operates primarily in the United States and international markets, generating revenue from collaborations and licensing agreements while investing heavily in research and development. With a strong cash position relative to liabilities, IOVA aims to advance multiple clinical programs toward regulatory approval.
Despite reporting a net loss of $391M in 2025 and operating losses exceeding $400M, IOVA maintained a healthy liquidity position with cash and equivalents of $163.1M against total liabilities of only $214.6M. The company's revenue surged to $263.5M in 2025 compared to $1.2M the prior year, driven by successful commercialization or milestone payments from key collaborations. However, the significant increase in operating expenses, particularly research and development of $300.3M and general administrative costs of $152.3M, indicates an aggressive expansion phase typical for pre-commercial biotech firms.
The global cell therapy and immunotherapy market is experiencing rapid growth, driven by unmet medical needs in oncology and advancements in gene editing technologies. Competition is intense among major pharmaceutical companies and specialized biotechs targeting similar indications like solid tumors and liquid cancers. Regulatory scrutiny from the FDA remains high for novel therapies, requiring extensive clinical data to demonstrate safety and efficacy before market entry.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $1.2M | $164.1M | $263.5M |
| Cost of Revenue | $0 | $10.8M | $124.0M | $173.2M |
| Gross Profit | $0 | $-9.6M | $40.1M | $90.3M |
| Operating Expenses | $398.9M | $451.0M | $435.4M | $493.7M |
| Operating Income | $-398.9M | $-460.6M | $-395.3M | $-403.4M |
| R&D | $294.8M | $344.1M | $282.3M | $300.3M |
| G&A | $104.1M | $106.9M | $153.0M | $152.3M |
| Stock-Based Comp | $84.0M | $62.6M | $109.6M | $61.6M |
| D&A | $9.3M | $11.6M | $12.0M | $12.9M |
| Depreciation | $9.3M | — | — | — |
| Amortization | — | $9.8M | $21.2M | $23.1M |
| Other OpEx | $0 | $0 | $0 | $41.1M |
| Non-Operating Income | $0 | $13.0M | $20.3M | $10.3M |
| Interest Income | $3.0M | $13.0M | $20.3M | $10.3M |
| Pre-Tax Income | $-398.9M | $-447.5M | $-375.0M | $-393.0M |
| Income Tax | $-3.0M | $-3.5M | $-2.8M | $-2.1M |
| Continuing Ops | $-395.9M | $-444.0M | $-372.2M | $-391.0M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-395.9M | $-444.0M | $-372.2M | $-391.0M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-395.9M | $-444.0M | $-372.2M | $-391.0M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $479.1M | $307.8M | $457.0M | $442.7M |
| Cash & Equivalents | $231.7M | $114.9M | $115.7M | $163.1M |
| Marketable Securities | $240.1M | $165.0M | $208.1M | $133.9M |
| Accounts Receivable | — | $151.0K | $69.3M | $82.4M |
| Inventory | — | $10.4M | $51.5M | $51.7M |
| Prepaid Expenses | $7.3M | $17.5M | $12.4M | $11.6M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $184.9M | $472.5M | $453.4M | $470.5M |
| PP&E (Net) | $105.2M | $114.0M | $109.1M | $131.1M |
| Operating Leases | $73.0M | $62.5M | $55.2M | $45.9M |
| Other LT Assets | $6.6M | $296.0M | $289.1M | $293.5M |
| Total Assets | $664.0M | $780.4M | $910.4M | $913.2M |
| Current Liabilities | $91.5M | $110.3M | $122.3M | $138.4M |
| Accounts Payable | $26.6M | $33.1M | $27.5M | $22.2M |
| Current Leases | $12.6M | $7.8M | $12.9M | $4.0M |
| Other Current Liab | $0 | $0 | $0 | $1.0M |
| Long-Term Liabilities | $72.9M | $85.4M | $77.7M | $76.2M |
| LT Operating Leases | $71.9M | $67.1M | $44.4M | $44.4M |
| Other LT Liab | $1.0M | $18.3M | $33.3M | $31.8M |
| Total Liabilities | $164.3M | $195.7M | $200.0M | $214.6M |
| Shareholders' Equity | $499.6M | $584.6M | $710.4M | $698.6M |
| Paid-In Capital | $2.07B | $2.59B | $3.10B | $3.46B |
| Retained Earnings | $-1.57B | $-2.01B | $-2.38B | $-2.78B |
| AOCI | $-902.0K | $2.5M | $-1.0M | $16.4M |
| Total L&E | $664.0M | $780.4M | $910.4M | $913.2M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-395.9M | $-444.0M | $-372.2M | $-391.0M |
| Non-Cash Adjustments | $101.8M | $48.1M | $-80.7M | $42.2M |
| Working Capital Changes | $1.4M | $34.1M | $99.9M | $46.4M |
| Cash from Operations | $-292.8M | $-361.8M | $-353.0M | $-302.4M |
| Capital Expenditures | $20.4M | $22.3M | $11.1M | $33.8M |
| Cash from Investing | $256.5M | $-155.2M | $-96.4M | $47.5M |
| Cash from Financing | $190.2M | $463.0M | $390.7M | $300.8M |
| FX Effect | $0 | $-2.7M | $-541.0K | $1.1M |
| Net Change in Cash | $153.8M | $-56.8M | $-59.3M | $47.0M |
| Beginning Cash | $84.3M | $238.2M | $181.3M | $122.1M |
| Ending Cash | $238.2M | $181.3M | $122.1M | $169.1M |
Revenue is primarily derived from strategic collaborations and licensing agreements with third-party pharmaceutical companies for the development of IOVA's proprietary T-cell receptor technologies, rather than direct product sales. The company focuses on oncology as its primary therapeutic area, targeting solid tumors through its novel cell therapy platform. A small portion of revenue may come from consulting services or grants, though operating expenses are dominated by research and development costs totaling over $300M annually.
The company faces significant clinical trial risks as its products are not yet approved, meaning future revenue is entirely dependent on successful Phase 2 or Phase 3 outcomes. IOVA has limited commercialization experience and relies heavily on external partners, creating dependency risks if collaborations fail or terminate. The biotechnology sector is highly competitive with numerous large pharmaceutical players entering the cell therapy space, potentially leading to pricing pressure or market saturation. Continued heavy cash burn for R&D could lead to a dilutive equity offering if current cash reserves are depleted before product approvals.
IOVA possesses a proprietary library of T-cell receptors specifically designed to target antigens expressed on solid tumors, offering a unique mechanism of action compared to traditional checkpoint inhibitors. The company benefits from strong strategic partnerships that provide upfront payments and milestone revenue, reducing immediate cash burn pressure while sharing development risk. IOVA's specialized expertise in developing bispecific T-cell receptor (BiTe) molecules provides a technological moat in the crowded immunotherapy landscape.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.